Brand Name
Alhemo
Generic Name
Concizumab
View Brand Information FDA approval date: February 19, 2025
Classification: Tissue Factor Pathway Inhibitor Antagonist
Form: Injection
What is Alhemo (Concizumab)?
Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A with or without FVIII inhibitors, hemophilia B with or without FIX inhibitors Alhemo is a tissue factor pathway inhibitor antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:, hemophilia A with or without FVIII inhibitors, hemophilia B with or without FIX inhibitors
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment